Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q2

4574.TEDINET S100RMXK
Period2023-01-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥2.5bn2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥5.0bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥1.9bn2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥396m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥2.4bn2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥510m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥3.4bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥2.5bn2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥492m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥2.8bn2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥514m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥4.9bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥514m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥2.8bn2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥15.6bnat 2023-06-30Cons.Assets
Total assets¥15.0bnat 2022-12-31Cons.Assets
Total assets¥17.4bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥6.5bnat 2023-06-30Cons.Liabilities
Total liabilities¥7.0bnat 2022-12-31Cons.Liabilities
Net assets / equity¥9.2bnat 2023-06-30Cons.Net assets
Net assets / equity¥8.0bnat 2022-12-31Cons.Net assets
Net assets / equity¥10.2bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥4.8bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.1bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥4.5bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥2.8bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.4bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥5.5bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow¥126m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥2.0bn2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥631m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow¥707m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow¥190m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥96m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥827m2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥997m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥501m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-11.362023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.762023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-112.262022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-64.172022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.052022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio58.7%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio53.5%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.4%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Otherother segmentsrevenue2023-01-01 → 2023-06-30¥2m
Otherother segmentsrevenue external2023-01-01 → 2023-06-30¥2m
Otherother segmentssegment profit2023-01-01 → 2023-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-06-30−¥492m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥370m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥407m
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥2.1bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥514m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-06-30¥2.5bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-06-30¥95m
Otherother segmentsrevenue2022-01-01 → 2022-06-30¥4m
Otherother segmentsrevenue external2022-01-01 → 2022-06-30¥4m
Otherother segmentssegment profit2022-01-01 → 2022-06-30−¥11m
Reconciling Itemsreconcilingsegment profit2022-01-01 → 2022-06-30−¥645m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥365m
jpcrp040300-q2r_E22560-000Infection Control Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥1.6bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥1.5bn
jpcrp040300-q2r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥117m
Total Of Reportable Segments And Otherssegment totalrevenue2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-01-01 → 2022-06-30¥1.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-01-01 → 2022-06-30−¥1.8bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 510
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任 あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)溝　　静太
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)塚本　　健
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration1857000000JPY
Net sales (5-year summary)CurrentYTDDuration2488000000JPY
Net sales (5-year summary)Prior1YearDuration5040000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration-2515000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration-510000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration-3352000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration-2798000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration-514000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-4895000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration-2658000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration-334000000JPY
Comprehensive income (5-year summary)Prior1YearDuration-4796000000JPY
Net assets (5-year summary)Prior1QuarterInstant10182000000JPY
Net assets (5-year summary)CurrentQuarterInstant9177000000JPY
Net assets (5-year summary)Prior1YearInstant8044000000JPY
Total assets (5-year summary)Prior1QuarterInstant17422000000JPY
Total assets (5-year summary)CurrentQuarterInstant15636000000JPY
Total assets (5-year summary)Prior1YearInstant15046000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration-64.17
Basic earnings loss per share (5-year summary)CurrentYTDDuration-11.36
Basic earnings loss per share (5-year summary)Prior1YearDuration-112.26
Diluted earnings per share (5-year summary)Prior1YTDDuration－
Diluted earnings per share (5-year summary)CurrentYTDDuration－
Diluted earnings per share (5-year summary)Prior1YearDuration－
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.584
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.587
Equity to asset ratio (5-year summary)Prior1YearInstant0.535
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration-631000000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration126000000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration-1994000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-96000000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration707000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration190000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration-501000000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration827000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration-997000000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant4379000000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant4511000000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant2797000000JPY
Basic earnings loss per share (5-year summary)Prior1QuarterDuration-24.05
Basic earnings loss per share (5-year summary)CurrentQuarterDuration-5.76
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember48236900
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember48536900
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant48236900
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant48536900

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass